FMP

FMP

Enter

ENTA - Enanta Pharmaceutica...

Financial Summary of Enanta Pharmaceuticals, Inc.(ENTA), Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs f

photo-url-https://financialmodelingprep.com/image-stock/ENTA.png

Enanta Pharmaceuticals, Inc.

ENTA

NASDAQ

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

14.68 USD

0.36 (2.45%)

About

ceo

Dr. Jay R. Luly Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

CIK

0001177648

ISIN

US29251M1062

CUSIP

29251M106

Address

500 Arsenal Street

Phone

617 607 0800

Country

US

Employee

145

IPO Date

Mar 21, 2013

Summary

CIK

0001177648

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

29251M106

ISIN

US29251M1062

Country

US

Price

14.68

Beta

0.6

Volume Avg.

178.49k

Market Cap

310.91M

Shares

-

52-Week

8.08-20.04

DCF

-8.55

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.35

P/B

-

Website

https://www.enanta.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ENTA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep